Fulgent Oncology
Kane Frazier currently serves as Vice President of Sales at both Fulgent Genetics since July 2024 and CSI Laboratories since December 2023. Previously, Kane held the position of Director of Business Development at M2GEN from November 2022 to December 2023, focusing on biotechnology and health informatics solutions. Kane's background includes significant experience at NeoGenomics Laboratories, where roles included Regional Director for the Southeast and Territory Business Manager from November 2007 to February 2022. Kane earned a Bachelor of Science degree in Public Relations, Advertising, and Applied Communication from the University of Florida between 1999 and 2003.
This person is not in any teams
This person is not in any offices
Fulgent Oncology
As a brand under Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years. Our in-house medical team works closely with pathologists, oncologists and technicians to provide comprehensive diagnostic testing and analysis throughout the United States and Caribbean. We invest in an expert medical team, the right technology and equipment, and training to provide a higher level of service to customers. Our testing services include: Flow Cytometry, FISH, Cytogenetic Analysis, Histology and Molecular Genetics. We also provide hematopathology and surgical pathology consultations and second opinions to support diagnosis and treatment decisions. We understand the need to deliver accurate and fast test results and we are driven every day by our mission to provide personalized cancer diagnostics to support pathologists in providing care to cancer patients.